slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,578
Current window 94,741-94,770
Pages 3,953
Rows per page 30
Component
94,741-94,770 of 118,578
17
The chart displays the breakdown of Construction vs Non-Owner Occupied loans within the CRE portfolio.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide highlights the cost and structure of subordinated debt as a component of the holding company's capital stack.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
24
MainStreet Bancshares | Results Presentation Deck | 31 slidesMainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
01
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
05
The slide uses a biological process diagram to illustrate how LNCs (Lipid Nanocochleates) leverage PS to enter cells.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
07
Uses a visual arrow-based timeline to show progression.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
13
Includes medical imagery of fungal cells and brain infection.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
17
Includes n/N counts and specific clinical trial footnotes regarding patient outcomes and data status.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction1 hit
19
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction1 hit
20
Clinical trial design diagram showing randomization into three arms with specific drug regimens over a 10-week period.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
Includes MIC comparison, tissue fungal burden (lung/brain), and survival curves.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The slide uses a map of the US to anchor the revenue projection and a list of four comparable deals to establish market precedent.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Market Sizing1 hit
26
Data presented as three distinct charts: line graph for weight, dot plot for congestion, and dot plot for viral titers.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
31
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
01
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
01
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
04
The slide details a strategic partnership involving equity investment and asset licensing.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
05
Includes details on upfront payments, private placement, and milestone/royalty structures.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
Includes study methodology timeline and statistical significance markers.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
24
The slide highlights rapid adoption compared to Saxenda and notes supply chain issues impacting Q4'21 and H1'22.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
28
The slide details the IP ownership status and patent expiration timelines for two specific drug candidates.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
30
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
01
Nuvalent | Investor Presentation Deck | 31 slidesNuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
06
The slide uses a human anatomy diagram to map specific TRK receptor inhibition (TRKB, TRKC, TRKA) to associated clinical side effects.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes list of authors and their institutional affiliations.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
11
The slide outlines the clinical trial structure, including patient eligibility criteria and study objectives for both phases.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The slide uses a process-flow style diagram to show how initial cohorts are expanded via back-filling and then filtered into a response-evaluable population.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
20
The slide uses a before-after-during progression (Baseline, 4 weeks, 8 weeks) to visualize drug efficacy.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
01
Organicell Regenerative Medicine | Investor Presentation Deck | 17 slidesOrganicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit